BIONTECH SE (BNTX) News
Filter BNTX News Items
BNTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BNTX News Highlights
- BNTX's 30 day story count now stands at 81.
- Over the past 29 days, the trend for BNTX's stories per day has been choppy and unclear. It has oscillated between 1 and 16.
- The most mentioned tickers in articles about BNTX are AGE, SE and PFE.
Latest BNTX News From Around the Web
Below are the latest news stories about BioNTech SE that investors may wish to consider to help them evaluate BNTX as an investment opportunity.
UPDATE 1-Pfizer asks UK regulator to approve vaccine for teenagers -The TelegraphPfizer Inc has formally asked the UK medical regulator for permission to use its COVID-19 vaccine for 12-to 15-year olds in Britain, the Telegraph reported on Tuesday. Pfizer and the MHRA did not immediately response to Reuters requests for comment. The move comes as U.S. regulators on Monday authorized Pfizer and BioNTech's COVID-19 vaccine for use in children as young as 12, widening the country's inoculation program as vaccination rates have slowed significantly. |
BioNTech Is No Longer a Buy, Says AnalystDespite some good news recently about the coronavirus vaccine it co-developed, BioNTech (NASDAQ: BNTX) has been hit with a recommendation downgrade. In a research note published on Tuesday, Bryan Garnier analyst Olga Smolentseva changed her view on the stock to neutral from the previous buy recommendation. At the same time, though, she significantly raised her price target on the stock, from $135 per share to $206. |
Pfizer and BioNTech's COVID-19 Vaccine Authorized by the FDA for AdolescentsParents are pleased, but the move won't change much for the drug companies from a financial perspective. |
Covid-19 Vaccine Data on Children Under 12 Expected by Late Fall, Officials SayAdministration medical adviser Anthony Fauci told a Senate panel that steps to vaccinate younger children will probably occur in stages, progressing younger and younger, as study evidence accumulates. |
Dow Jones Dives 600 Points As Stock Market Sells Off; Nasdaq Cuts Steep LossesStocks were back near session lows Tuesday afternoon as the Dow Jones Industrial Average widened its loss to more than 600 points. |
Perrigo (PRGO) Q1 Earnings Miss Estimates, Revenues In LinePerrigo (PRGO) reports dismal first-quarter 2021 results. The COVID-19 pandemic continues to hurt the company's top line. |
Axsome's (AXSM) Q1 Earnings Top, AXS-05 Launch in FocusAxsome (AXSM) reports narrower-than-expected loss for the first quarter of 2021. The company is gearing up to launch its first commercial product, AXS-05, following a potential approval. |
Is Pfizer Stock A Buy As It Eyes $26 Billion In Full-Year Covid Vaccine Sales?Pfizer stock briefly broke out in May after the company called for $26 billion in full-year coronavirus vaccine sales. Is PFE stock a buy right now? |
Company News for May 11, 2021Companies in the news are: BNTX, WB, ES, J |
FDA Gives Emergency Use Nod to Pfizer/BioNTech COVID-19 Vaccine in AdolescentsPfizer (PFE) and BioNTech (BNTX) have received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for their COVID-19 vaccine to be used in adolescents. The expanded approval now includes the 12 to 15 age group. This is the first COVID-19 vaccine to receive U.S. approval for this age group. Pfizer Chairman and CEO Albert Bourla said, “Today’s expansion of our EUA represents a significant step forward in helping the U.S. government broaden its vaccination program and help protect adolescents before the start of the next school year.” (See Pfizer stock analysis on TipRanks) Bourla added, “We are grateful to all of our clinical trial volunteers and their families, whose courage helped make this milestone possible.” This approval is based on results from a Pha... |